7-6003996-C-G
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BS1_Supporting
The NM_000535.7(PMS2):c.226G>C(p.Glu76Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000118 in 1,603,834 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000535.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 250858Hom.: 0 AF XY: 0.0000369 AC XY: 5AN XY: 135668
GnomAD4 exome AF: 0.00000620 AC: 9AN: 1451696Hom.: 0 Cov.: 27 AF XY: 0.00000830 AC XY: 6AN XY: 722896
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74314
ClinVar
Submissions by phenotype
not provided Uncertain:2
In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
The PMS2 c.226G>C (p.Glu76Gln) variant has been observed in 2 breast cancer cases in a large-scale breast cancer association study (see LOVD (http://databases.lovd.nl/shared/) and PMID: 33471991 (2021)).The frequency of this variant in the general population, 0.00012 (4/34582 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.E76Q variant (also known as c.226G>C), located in coding exon 3 of the PMS2 gene, results from a G to C substitution at nucleotide position 226. The glutamic acid at codon 76 is replaced by glutamine, an amino acid with highly similar properties. This variant was identified in 1 of 68 unrelated individuals with a personal and/or family history of breast and/or ovarian cancer (Zidan J et al. Breast Cancer Res Treat, 2017 Dec;166:881-885). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces glutamic acid with glutamine at codon 76 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with PMS2-related disorders in the literature. This variant has been identified in 6/250858 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Lynch syndrome Uncertain:1
This missense variant replaces glutamic acid with glutamine at codon 76 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with PMS2-related disorders in the literature. This variant has been identified in 6/250858 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 76 of the PMS2 protein (p.Glu76Gln). This variant is present in population databases (rs371682056, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PMS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 233194). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PMS2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Lynch syndrome 4 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at